Research Funding

Postdoctoral Position – RNA Sequencing

La Jolla Institute for Allergy & Immunology

This postdoc will be responsible for performing and analyzing single-cell and bulk RNA-Seq assays on a large, multi-center project characterizing the memory T cell immune signatures associated with Mycobacterium tuberculosis and dengue virus infection. These analyses will define the transcriptomic profiles of CD4+ and CD8+ T cells in individuals previously exposed to either pathogen, currently experiencing active disease, or who have been vaccinated; the overall goal is to determine whether certain immune signatures are associated with preferential expansion or contraction of certain pre-existing subsets of T cells. This is a large-scale study employing samples from numerous sites around the globe, allowing conclusions regarding the extent of generalizability.

To submit your application, please click on this Apply through website link.

Desired skills and experience

The ideal postdoctoral candidate will have experience in molecular biology and immunology,. The candidate should also be comfortable working in a large, interdisciplinary research group, as this project will involve extensive interaction with immunologists, clinical coordinators, and bioinformaticians.

Interested individuals must include their curriculum vitae and the names of three references.

About the employer

Our independent, non-profit research institute is currently seeking a highly motivated researcher for an immediate opening in the research group of Dr. Alessandro Sette.

Successful candidates will join an interdisciplinary group of researchers dedicated to the identification and characterization of protective T cell epitopes from a variety of complex antigens, such as allergens, viruses, and bacteria.

FY15 Peer Reviewed Cancer Research Program RFA

The FY15 Defense Appropriations Act provides $50 million (M) to the Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The executing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY15 PRCRP Program Announcement and General Application Instructions for the following award mechanism are posted on the website.
Congressionally Directed Topic Areas: To be considered for funding, applications for the FY15 PRCRP must address at least one of the Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), or ovarian cancer will not be accepted. The FY15 PRCRP Topic Areas are listed below:

  • Colorectal cancer
  • Genetic cancer
  • Kidney cancer
  • Listeria vaccine for cancer
  • Liver cancer (New for FY15)
  • Melanoma and other skin cancers
  • Mesothelioma
  • Myeloproliferative disorders
  • Neuroblastoma
  • Pancreatic cancer
  • Stomach cancer (New for FY15)

To address the cancer health needs of both deployed and non-deployed personnel, their dependents, retirees, and Veterans, the FY15 PRCRP encourages studies that are responsive to the FY15 Military Relevance Focus Areas listed below:

  • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, and environmental carcinogens).
  • Gaps in cancer prevention, screening, early detection, diagnosis, treatment, and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military members, Veterans, and their beneficiaries.

Horizon Award – Letter of Intent due August 11, 2015

PI:  Both pre-doctoral candidates and postdoctoral fellows are eligible.

Mentor: The Mentor must be an experienced cancer researcher as demonstrated by a strong record of funding and publications. In addition, the Mentor must demonstrate a commitment to advancing the PI’s career in cancer research.

The PI and the Mentor must be at the same organization

  • Letter of Intent is required.
  • Supports junior level scientists to conduct impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor)
  • Challenges junior scientists to develop and implement research in the cancer field
  • Emphasis on discovery
  • Must address at least one of the FY15 PRCRP Topic Areas
  • Encouraged to address at least one of the FY15 PRCRP Military Relevance Focus Areas
  • Preliminary data are not required

Clinical trials are not allowed

    • Maximum funding for the entire period of performance is $75,000 for direct costs (plus indirect costs)

Maximum period of performance is 1 year

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that are available for electronic downloading from the website. The application package containing the required forms for each award mechanism will also be found on A listing of all CDMRP funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Submission deadlines are not available until the Program Announcements are released. Requests for email notification of the Program Announcements release may be sent to For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:
CDMRP Help Desk 301-6682-5507

2015 RFA Center for Leukemia and Lymphoma Research Pilot Projects

Deadline:  August 1st, 2015

The Center for Leukemia and Lymphoma Research (CLLR) at UNMC FPBCC desires to support pilot research projects that promote the identification of novel biomarkers and compounds for targeted therapy in hematological malignancies, including, but not limited to, lymphoma, leukemia and multiple myeloma. Two awards up to $50,000 for one year per grant are available each cycle. Potential supplemental fund may be available with demonstrated significant progress of the project.  The deadline for this cycle of application is August 1st, 2015 with anticipated funding for successful applications started on September 15th, 2015.

Prior to submission, each applicant is strongly encouraged to contact Center Co-leaders Julie Vose and Kai Fu to determine whether their research project fits within CLLR programmatic interests.  Approved applications must be e-mailed as a single, complete PDF to Dr. Kai Fu ( Please include the “CLLR 2015 RFA” and the last name of the Principal Investigator in the subject line of the e-mail. Following receipt of each application, the applicant will receive an e-mail confirming receipt. Funding decisions will be made following review of each application by CLLR and FPBCC senior leadership.